STOCKHOLM, Sweden, April 4, 2005 (PRIMEZONE) -- Vitrolife's annual report (in Swedish) has now been published and can be downloaded as a pdf file, either through the link below or from www.vitrolife.com. A printed copy can be ordered at the company website www.vitrolife.com. The annual report will be sent out to Nordic shareholders during week 14.
Questions should be addressed to: Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.
Vitrolife today has over 70 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there is a subsidiary in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=84678&fn=wkr0001.pdf